Wedbush Reiterates Outperform on Maze Therapeutics, Maintains $48 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 42.7%

Neg 0% Neu 42.7% Pos 0%

Wedbush analyst Laura Chico reiterates Maze Therapeutics (NASDAQ:MAZE) with a Outperform and maintains $48 price target.